X

Lupin Limited Q4FY23 Earnings Story

Lupin manufactures pharmaceuticals as a line of business. Globally, APIs, biotechnology products, and generic formulations are all developed and marketed by Lupin Limited. The firm is a worldwide leader in the Anti-TB and Cephalosporins segments and has a substantial presence in the Cardiovascular, Diabetology, Asthma, Paediatrics, and Central Nervous system markets, among others.

Financial Results:

  • Lupin Ltd. reported Total Income for Q4FY23 of ₹ 4,430 Crores up from ₹ 3,883 Crore year on year, a rise of 14%.

  • Total Expenses for Q4FY23 of ₹ 4,209 Crores up from ₹ 3,984 Crores year on year, rise of 6%.

  • Consolidated Net Profit of ₹ 259 Crores, up from a loss of ₹ 850 Crores in the same quarter of the previous year.

  • The Earnings per Share is ₹ 5.16, down 62% from ₹ -11.40 in the same quarter of the previous year.
Related Post